Vorasidenib, an oral dual IDH1/IDH2 inhibitor, received FDA approval in August 2024 for IDH-mutant grade 2 gliomas, based on the phase 3 INDIGO trial (NCT04164901). The gene discussed is IDH2; the disease is central nervous system cancer.